Memantine Resin Complex Extended Release Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current extended release oral dosage forms face challenges in consistently maintaining effective blood levels and preventing dose dumping, particularly with memantine, due to variability in release rates influenced by diet, water intake, and intestinal content, and the use of ion-exchange resins is limited by their sensitivity to enzymatic degradation and variability in ion concentrations.
Innovation Solution
The development of an oral extended release composition using memantine or its pharmaceutically acceptable salt combined with resin-complexation technology, including specific particle size ranges and additional active ingredients like donepezil, to create a stable and controlled release system that prevents dose dumping and maintains therapeutic levels for up to 24 hours, utilizing a process of drug-resin complexation, matrix preparation, and extended release coating.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If ion-exchange resins are used for extended release, then drug release is modulated, but release rate becomes variable due to diet, water intake and intestinal content
Solution Approach 1:
The patent changes the release mechanism from ion-exchange (concentration-dependent) to osmotic pressure-driven release (pressure-dependent). The osmotic pump system uses semi-permeable membranes and osmotically active agents to generate consistent internal pressure that drives drug release at a constant rate independent of external factors like diet and water intake.
Solution Approach 2:
The patent replaces the chemical ion-exchange mechanism with a physical osmotic mechanism. Instead of relying on ion concentration gradients and chemical reactions, the system uses osmotic pressure differential across a semi-permeable membrane to drive controlled drug release, providing more reliable and predictable kinetics.
2Duration of action of moving object
If controlled release dosage form is used, then extended release is achieved, but dose dumping occurs increasing toxicity risk
Solution Approach 1:
The patent incorporates release-retarding agents and structural design elements during manufacturing that pre-establish controlled release characteristics. The osmotic pump structure and matrix formulation are designed in advance to prevent sudden drug release, ensuring consistent rate-controlled delivery even under varying gastrointestinal conditions.
Solution Approach 2:
The patent uses semi-permeable membranes and release-retarding agents as intermediary layers between the drug reservoir and the gastrointestinal environment. These intermediaries regulate drug release by controlling permeability and generating osmotic pressure, preventing direct contact and sudden release of the drug into the bloodstream.
3Duration of action of moving object
If ion-exchange resins are used, then drug retarding properties are achieved, but release rate is affected by variability in ion concentrations
Solution Approach 1:
The patent replaces the chemical ion-exchange mechanism with a physical osmotic mechanism. Instead of relying on ion concentration gradients and chemical reactions, the system uses osmotic pressure differential across a semi-permeable membrane to drive controlled drug release, providing more reliable and predictable kinetics independent of gastrointestinal ion variability.
Solution Approach 2:
The patent changes the release mechanism from ion-exchange (concentration-dependent) to osmotic pressure-driven release (pressure-dependent). The osmotic pump system uses semi-permeable membranes and osmotically active agents to generate consistent internal pressure that drives drug release at a constant rate independent of external factors like diet and water intake.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively maintains therapeutic plasma levels of memantine for extended periods, preventing dose dumping and improving treatment efficacy for CNS-related conditions such as Alzheimer's and Parkinson's disease, while ensuring stability and controlled release.
Implementation Method 1
Ion-exchange resins are cross-linked synthetic high molecular weight solid water insoluble usually white or yellowish, fabricated from organic polymer (polyelectrolyte) having ionisable functional group. Complexes between IER and drugs are known as ion exchange resinates
Implementation Method 2
The drug resinates can also be used as a drug reservoir, which will change the drug release in hydrophilic polymer composition
Data Source
AI summary
The present invention relates to oral extended release composition, comprising memantine or its pharmaceutically acceptable salt as an active ingredient, resin complexation ingredient, release retardant, extended release coating system and the composition further comprising diluents, viscosity increasing agents, glidants, sweeteners, stabilizing agents, preservatives and other pharmaceutically acceptable excipients, wherein the drug-resin complex and drug-resin complex matrix particulates and coated drug-resin complex particulates have the specific particle size range. The present invention also relates to a process for the preparation of memantine or its salt oral extended release composition comprising the steps of drug-resin complexation, matrix resinate/particulates preparation process followed by extended release coating. The present invention also relates to oral extended release composition comprising memantine or its pharmaceutically acceptable salt as an active ingredient and pharmaceutically acceptable excipients using extended release resin-complexation technology, further comprising additional active ingredient is in its immediate release form.